SCHEMBL16092113

SCHEMBL16092113

CN(C)c1cc(-c2ccncc2)c(-c2cccc3ccccc23)nn1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 9/20 1.00
MAPK11 Q15759 8/20 1.00
CSNK1D P48730 6/20 0.67
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 2/20 0.43
MAPT P10636 2/20 0.43
HPGD P15428 2/20 0.43
NPC1 O15118 1/20 0.43
LMNA P02545 1/20 0.43
MAPK1 P28482 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HSD17B10 Q99714 1/20 0.43
BCHE P06276 1/20 0.40
MAPK13 O15264 1/20 0.39
GCGR P47871 1/20 0.39
MAPK12 P53778 1/20 0.39
TNF P01375 1/20 0.39
ADORA2A P29274 1/20 0.39
ADORA1 P30542 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16092215 0.90 MAPK11 (0.81) MAPK14MAPK11CSNK1DLMNATNF
SCHEMBL16092107 0.88 MAPK14 (0.78) MAPK14MAPK11CSNK1DKDM4EALDH1A1
SCHEMBL17728198 0.87 MAPK14 (0.76) MAPK14MAPK11CSNK1DMAPK13GCGR
SCHEMBL30360182 0.86 MAPK14 (0.76) MAPK14MAPK11CSNK1DKDM4EALDH1A1
SCHEMBL21219601 0.86 MAPK14 (0.76) MAPK14MAPK11CSNK1DKDM4EALDH1A1
SCHEMBL17790084 0.86 MAPK14 (0.76) MAPK14MAPK11CSNK1DMAPK13GCGR
SCHEMBL17728168 0.86 MAPK14 (0.74) MAPK14MAPK11CSNK1DKDM4EALDH1A1
SCHEMBL16092217 0.83 MAPK14 (0.71) MAPK14MAPK11CSNK1DADORA2AADORA1
SCHEMBL16092103 0.82 MAPK14 (0.70) MAPK14MAPK11CSNK1DKDM4EALDH1A1
SCHEMBL17728133 0.81 MAPK11 (0.67) MAPK14MAPK11CSNK1DKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3842424-B1 MAP KINASE MODULATORS AND USES THEREOF IN THE TRETAMENT OF TAUOPATHIES UNIV COLUMBIA (US) 2024-12-11 EP disclosed
US-11566016-B2 MAP kinase modulators and uses thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2023-01-31 US disclosed
US-11566016-B2 MAP kinase modulators and uses thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2023-01-31 US disclosed
US-20220009905-A1 MAP KINASE MODULATORS AND USES THEREOF NORTHWESTERN UNIVERSITY 2022-01-13 US disclosed
US-20220009905-A1 MAP KINASE MODULATORS AND USES THEREOF NORTHWESTERN UNIVERSITY 2022-01-13 US disclosed
US-11149020-B2 MAP kinase modulators and uses thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2021-10-19 US disclosed
US-11149020-B2 MAP kinase modulators and uses thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2021-10-19 US disclosed
EP-3842424-A1 MAP KINASE MODULATORS AND USES THEREOF IN THE TRETAMENT OF TAUOPATHIES The Trustees of Columbia University in the City of New York (US) 2021-06-30 EP disclosed
EP-3521284-B1 PYRAZINE COMPOUNDS AS MAP KINASE MODULATORS AND USES THEREOF UNIV COLUMBIA (US) 2020-12-02 EP disclosed
EP-3521284-B1 PYRAZINE COMPOUNDS AS MAP KINASE MODULATORS AND USES THEREOF UNIV COLUMBIA (US) 2020-12-02 EP disclosed
US-20170369472-A1 MAP KINASE MODULATORS AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2017-12-28 US disclosed
US-9783525-B2 Map kinase modulators and uses thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2017-10-10 US disclosed
US-9783525-B2 Map kinase modulators and uses thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2017-10-10 US disclosed
US-9783525-B2 Map kinase modulators and uses thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2017-10-10 US disclosed
US-20160151366-A1 Compositions and Methods for Treating Autism Spectrum Disorders NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2016-06-02 US disclosed
US-20160151366-A1 Compositions and Methods for Treating Autism Spectrum Disorders NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2016-06-02 US disclosed
US-20160130253-A1 MAP KINASE MODULATORS AND USES THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2016-05-12 US disclosed
US-20160130253-A1 MAP KINASE MODULATORS AND USES THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2016-05-12 US disclosed
US-20160130253-A1 MAP KINASE MODULATORS AND USES THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2016-05-12 US disclosed
WO-2014145485-A2 MAP KINASE MODULATORS AND USES THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2014-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160130253-A1 MAP KINASE MODULATORS AND USES THEREOF MAPK1, MAP3K1, MAP3K2 MAPK14 40/4885MAPK11 47/4885CSNK1D 617/4885
US-20170369472-A1 MAP KINASE MODULATORS AND USES THEREOF MAPK1, MAP3K1, MAP3K2 MAPK14 40/4885MAPK11 47/4885CSNK1D 617/4885
US-11566016-B2 MAP kinase modulators and uses thereof MAPK1, MAP3K1, MAP3K2 MAPK14 40/4885MAPK11 47/4885CSNK1D 617/4885
US-11149020-B2 MAP kinase modulators and uses thereof MAPK1, MAP3K1, MAP3K2 MAPK14 40/4885MAPK11 47/4885CSNK1D 617/4885
US-20160151366-A1 Compositions and Methods for Treating Autism Spectrum Disorders GRIN2A, GRIN2C, NTRK2 MAPK14 124/4885MAPK11 66/4885CSNK1D 271/4885
US-20220009905-A1 MAP KINASE MODULATORS AND USES THEREOF MAPK1, MAP3K1, MAP3K2 MAPK14 40/4885MAPK11 47/4885CSNK1D 617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.